MA53503A - Polythérapie faisant appel à des antagonistes de récepteurs 4 de chimiokines c-c (ccr4) et à un ou plusieurs inhibiteurs de points de contrôle immunitaires - Google Patents

Polythérapie faisant appel à des antagonistes de récepteurs 4 de chimiokines c-c (ccr4) et à un ou plusieurs inhibiteurs de points de contrôle immunitaires

Info

Publication number
MA53503A
MA53503A MA053503A MA53503A MA53503A MA 53503 A MA53503 A MA 53503A MA 053503 A MA053503 A MA 053503A MA 53503 A MA53503 A MA 53503A MA 53503 A MA53503 A MA 53503A
Authority
MA
Morocco
Prior art keywords
ccr4
antagonists
immune checkpoint
chemokine receptor
checkpoint inhibitors
Prior art date
Application number
MA053503A
Other languages
English (en)
Inventor
Shijie Li
Venkat Reddy Mali
Rajinder Singh
Ju Yang
Penglie Zhang
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of MA53503A publication Critical patent/MA53503A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/82—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/852—Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA053503A 2018-08-29 2019-08-28 Polythérapie faisant appel à des antagonistes de récepteurs 4 de chimiokines c-c (ccr4) et à un ou plusieurs inhibiteurs de points de contrôle immunitaires MA53503A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862724412P 2018-08-29 2018-08-29
US201862771853P 2018-11-27 2018-11-27

Publications (1)

Publication Number Publication Date
MA53503A true MA53503A (fr) 2021-07-07

Family

ID=69639506

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053503A MA53503A (fr) 2018-08-29 2019-08-28 Polythérapie faisant appel à des antagonistes de récepteurs 4 de chimiokines c-c (ccr4) et à un ou plusieurs inhibiteurs de points de contrôle immunitaires

Country Status (14)

Country Link
US (2) US11446289B2 (fr)
EP (1) EP3843734A4 (fr)
JP (1) JP2021536442A (fr)
KR (1) KR20210053306A (fr)
CN (1) CN112601526A (fr)
AU (1) AU2019327430A1 (fr)
BR (1) BR112021002928A2 (fr)
CA (1) CA3109498A1 (fr)
IL (1) IL280831B2 (fr)
MA (1) MA53503A (fr)
MX (1) MX2021002302A (fr)
SG (1) SG11202101454PA (fr)
TW (1) TW202023555A (fr)
WO (1) WO2020047030A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX356163B (es) 2011-12-01 2018-05-16 Chemocentryx Inc Anilinas sustituidas como antagonistas de ccr(4).
US11446289B2 (en) * 2018-08-29 2022-09-20 Chemocentryx, Inc. Combination therapy using C-C chemokine receptor 4 (CCR4) antagonists and one or more immune checkpoint inhibitors
KR20230149729A (ko) * 2022-04-19 2023-10-27 케모센트릭스, 인크. Ccr4 길항제

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003256923A1 (en) 2002-07-31 2004-02-16 Smithkline Beecham Corporation Substituted benzanilides as modulators of the ccr5 receptor
JP2007210887A (ja) 2004-06-21 2007-08-23 Astellas Pharma Inc 縮合二環性ピリミジン誘導体
US20090182140A1 (en) 2005-12-02 2009-07-16 Mitsubishi Tanabe Pharma Corporation Alicyclic Heterocyclic Compound
EP2240204A1 (fr) 2008-02-04 2010-10-20 Medarex, Inc. Anticorps anti-clta-4 avec blocage réduit de la liaison de ctla-4 à b7 et leurs utilisations
WO2011050566A1 (fr) 2009-10-26 2011-05-05 中国石油化工股份有限公司 Catalyseur non métallocène supporté, son procédé de préparation et ses utilisations
WO2011050565A1 (fr) 2009-10-26 2011-05-05 中国石油化工股份有限公司 Catalyseur non métallocène supporté, son procédé de fabrication et ses applications
US8541522B2 (en) 2009-10-28 2013-09-24 Exxonmobil Chemical Patents Inc. Catalyst compounds and use thereof
WO2011057469A1 (fr) 2009-11-13 2011-05-19 中国石油化工股份有限公司 Catalyseur non-métallocène supporté et son procédé de préparation et ses utilisations
US8957169B2 (en) 2009-11-13 2015-02-17 China Petroleum & Chemical Corp. Supported nonmetallocene catalyst, preparation and use thereof
DK2835131T3 (en) 2010-12-14 2017-12-04 Electrophoretics Ltd Casein kinase 1 delta inhibitors (CK1 delta)
MX356163B (es) 2011-12-01 2018-05-16 Chemocentryx Inc Anilinas sustituidas como antagonistas de ccr(4).
CN107252485A (zh) * 2013-04-03 2017-10-17 Ibc药品公司 用于诱导对疾病的免疫应答的组合疗法
US11236139B2 (en) * 2014-11-05 2022-02-01 The Regents Of The University Of California Combination immunotherapy
SG10201603721TA (en) 2016-05-10 2017-12-28 Agency Science Tech & Res Anti-CTLA-4 Antibodies
CN109803651B (zh) * 2016-06-27 2022-05-31 凯莫森特里克斯股份有限公司 免疫调节剂化合物
KR102566924B1 (ko) * 2016-07-29 2023-08-11 랩트 테라퓨틱스, 인크. 케모카인 수용체 조절제 및 이의 용도
WO2018035710A1 (fr) 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anticorps anti-ctla4
TW201825119A (zh) * 2016-11-30 2018-07-16 日商協和醱酵麒麟有限公司 使用抗ccr4抗體及抗pd-1抗體治療癌症之方法
US11446289B2 (en) * 2018-08-29 2022-09-20 Chemocentryx, Inc. Combination therapy using C-C chemokine receptor 4 (CCR4) antagonists and one or more immune checkpoint inhibitors

Also Published As

Publication number Publication date
SG11202101454PA (en) 2021-03-30
EP3843734A1 (fr) 2021-07-07
AU2019327430A1 (en) 2021-03-18
WO2020047030A1 (fr) 2020-03-05
US20200069673A1 (en) 2020-03-05
BR112021002928A2 (pt) 2021-05-11
KR20210053306A (ko) 2021-05-11
US11446289B2 (en) 2022-09-20
IL280831B1 (en) 2024-01-01
TW202023555A (zh) 2020-07-01
MX2021002302A (es) 2021-04-28
EP3843734A4 (fr) 2022-05-25
CN112601526A (zh) 2021-04-02
IL280831A (en) 2021-04-29
JP2021536442A (ja) 2021-12-27
US20230097128A1 (en) 2023-03-30
IL280831B2 (en) 2024-05-01
CA3109498A1 (fr) 2020-03-05

Similar Documents

Publication Publication Date Title
MA53503A (fr) Polythérapie faisant appel à des antagonistes de récepteurs 4 de chimiokines c-c (ccr4) et à un ou plusieurs inhibiteurs de points de contrôle immunitaires
DK3806955T3 (da) GLP-1-receptoragonister og anvendelser deraf
DK3806855T5 (da) GLP-1-receptoragonister og anvendelser deraf
DK3707159T3 (da) Hidtil ukendte modificerede t-cellereceptorer og immunterapi med anvendelse deraf
AR107303A1 (es) Métodos de tratamiento de cánceres positivos para ace utilizando antagonistas de unión a eje pd-1 y anticuerpos biespecíficos anti-ace / anti-cd3, uso, composición, kit
BR112017018715A2 (pt) agonista de receptor de angiotensina ii para tratar fibrose pulmonar
EA202190377A9 (ru) Композиции ингибиторов cxcr4 и способы получения и применения
MA46716A (fr) Polythérapie de thérapie cellulaire et d'inhibiteur de la microglie
DK3655401T3 (da) Tlr7/8-antagonister og anvendelser deraf
IL280479A (en) TLR7/8 antagonists and their use
CO2020015923A2 (es) Antagonista de gremlin-1 para la prevención y tratamiento del cáncer
IL273188A (en) Treatment with a combination of chemokine receptor 2 (CCR2) inhibitors and a PD-1/PD-L1 inhibitor
CL2021001432A1 (es) Terapia de combinación de radioinmunoconjugados con inhibidores de daños y reparaciones del adn
EP3712144C0 (fr) Antagoniste du récepteur p2x3 et/ou p2x2/3, composition pharmaceutique le comprenant et son utilisation
IL283755A (en) Non-atp/catalytic site p38 mitogen activated protein kinase inhibitors, compositions comprising same and uses thereof
IL277144A (en) Adenosine receptor antagonists and uses thereof
IL281802A (en) Use of an inhibitor of an ent family transporter in the treatment of cancer and combination thereof with an adenosine receptor antagonist
JOP20190040A1 (ar) توليفة من ناهضات fxr
IL291034A (en) Radiolabeling methods for grpr antagonists and their kits
MX2021010989A (es) Formulacion que incluye una combinacion de la hormona beta-endorfina y adrenocorticotropica.
MA55799A (fr) Polythérapies comprenant de l'aprémilast et des inhibiteurs de tyk2
IL290200A (en) Use of kv1.3 voltage-gated potassium channel antagonists for the treatment of chronic and acute pain
NZ738876A (en) Motile sperm domain containing protein 2 and inflammation
MA51128A (fr) Inhibiteurs c5ar destinés à être utilisés dans le traitement de la douleur iatrogène induite par la chimiothérapie
MA52691A (fr) Compositions à base de statine et procédés destinés à être utilisés dans le traitement de synucléinopathies